Prothymosin α is an evolutionary conserved protein covalently linked to a small RNA  by Makarova, Tatyana et al.
Volume 257, number 2, 247-250 FEB 07766 
Prothymosin a is an evolutionary conserved 
a small RNA 
November 1989 
protein covalently linked to 
Tatyana Makarova, Nickolay Grebenshikov, Cesiy Egorov, Andrey Vartapetian and Alexey Bogdanov 
Belozersky Laboratory of Molecular Biology and Bioorganic Chemistry, A4oscow State University, Moscow 119899, USSR 
Received 5September 1989 
A 13 kDa protein, covalently linked to a small RNA from the cytoplasm of mouse cells, was studied. Sequence analysis of its tryptic peptides 
revealed that the RNA-linked protein is identical to prothymosin a. Very similar RNA-protein complexes were identified in human, bovine and 
yeast cells. Tryptic peptide maps of 12SI-labelled RNA-linked proteins of diverse origin demonstrated their marked similarity, thus indicating high 
evolutionary conservation of prothymosin a from yeast o man. 
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1. INTRODUCTION 
RNA genomes of a number of animal and plant 
viruses are known to possess at their 5 ‘-termini a 
covalently linked viral protein (review [l]). Recently, 
we have found a cellular protein covalently bound to a 
small RNA in the cytoplasm of mouse cells. This 
13 kDa protein was shown to be attached to an RNA 
molecule of about 20 nucleotides long, apparently to its 
5 ‘-end [2]. In this paper we present evidence that the 
RNA-linked protein is identical to prothymosin cy, an 
extremely acidic protein previously identified as a 
possible precursor of an immunomodulating peptide 
[3]. Very similar RNA-protein complexes were iden- 
tified in a number of eukaryotic cells, including human, 
bovine and yeast. Analysis of peptide maps showed 
that the RNA-linked proteins of diverse origin are 
structurally very similar, which testifies to high evolu- 
tionary conservation of prothymosin cy. Moreover, 
identification of prothymosin cr in yeast suggests that, 
apart from its immunomodulating activity, it probably 
provides some more general function in the cell. 
2. MATERIALS AND METHODS 
The source of covalent RNA-protein complex was the RNA 
preparation from mouse Krebs II ascites carcinoma cells, obtained as 
described in [2]. High-molecular weight RNA was eliminated by 
precipitation with 2 M lithium chloride and 2 M urea; supernatant 
was ethanol precipitated and chromatographed on DEAE-cellulose 
column. The complex was eluted with 0.3 M sodium chloride. 
For the final purification of the RNA-protein complex and for the 
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separation of tryptic peptides the material was fractionated by 
reversed-phase HPLC using ‘Ultrasphere-octyl’ 4.6 x 150 mm col- 
umn at 40°C in 0.1% trifluoroacetic acid. A linear gradient of 
isopropanol of 0 to 60% was used for RNA-protein isolation, and of 
0 to 30% for peptide fractionation. 
Protein labelling with the 125I Bolton and Hunter reagent was 
described in [2]. Hydrolysis of the RNA-bound protein with TPCK- 
trypsin (0.01 mg/ml, Worthington) was performed in 100 mM Tris- 
HCl, pH 8, for 2 h at 37°C. Two-dimensional peptide mapping was 
performed on cellulose-coated thin layer sheets. First dimension: 
electrophoresis in acetic acid/formic acid/water, 15 : 5 : 80, v/v; se- 
cond dimension: chromatography in butanol/pyridine/acetic 
acid/water, 25: 10:4: 12, v/v. 
Automated Edman degradation was carried out with an Applied 
Biosystems model 47OA/12OA gas-phase sequencer. The search for 
homologous protein sequences in the NBRF protein databank was 
performed with the ‘MicroGenie’ programme (Beckman). 
3. RESULTS 
3.1. The RNA-linked protein is prothymosin a 
In order to purify the covalent RNA-protein complex 
from mouse Krebs II cells, the preparation of the 
cytoplasmic RNA was used, which has been separated 
from the non-covalently bound proteins by repeated 
phenol-SDS extraction, as described earlier [2]. RNA 
fractionation (see section 2) has permitted one to obtain 
a preparation of the complex suitable for the analysis 
by reversed-phase HPLC. The HPLC-purified material 
(fig.lA, fractions 34-35) proved to be homogeneous, 
as judged by the electrophoresis in 8% PAG, and com- 
igrated with the 12’I-labelled authentic RNA-protein 
complex (fig.3, lane 7). 
Direct sequencing of the protein moiety of the com- 
plex failed, presumably due to the blocked N-terminus. 
Therefore, the RNA-linked protein was hydrolyzed 
with trypsin and the peptides were fractionated by 
reversed-phase HPLC (fig. 1B). Peptides I-V were 
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Pig. 1. (A) Purification of the covalent RNA-protein complex from mouse cells by HPLC. (B) Fractionation of tryptic peptides of the RNA-linked 
protein by HPLC. 
chosen for sequence analysis. The resultant amino acid 
sequences of these peptides, derived from the mouse 
RNA-linked protein, are shown in table 1. The peptides 
turned out to be extremely acidic and did not contain 
aromatic or sulfur-containing amino acids. Peptide V 
was not sequenced to its very C-terminus because of its 
length and presence of long stretches of glutamic acid 
residues. Peptide IV was resistant to the Edman 
degradation, most likely due to the blocking group at 
its N-terminus. This suggests that it represents the 
amino-terminus of the RNA-bound protein. 
Amino acid sequence of peptide III was used for a 
computer-assisted search for homologous protein se- 
quences in the protein sequence database. The only 
protein identified, which contained this sequence, was 
rat prothymosin LY, an 111 amino acid long protein, 
which indeed has a blocked (acetylated) N-terminus [3]. 
Moreover, prothymosin cy contains the amino acid se- 
Table 1 
The primary structures of tryptic peptides of the mouse RNA-linked 
protein” 
NN Sequence 
I q)bLK’7 
II 90VAEDDEDDDVETK’02 
III 2’EVVEEAENGR30 
IV blocked N-terminus (‘-‘w 
V “DAPANGNAQNEENGEQEADNEVDEEEEEGGEEEEEEE6’. . 
a Numbers indicate the position of the corresponding peptide in the rat 
prothymosin (Y sequence (see fig.2) 
b A small amount of alanine was also detectable at this step 
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Fig.2. Amino acid sequence of tryptic peptides of the mouse RNA- 
linked protein (underlined) and of rat prothymosin a [9]. Basic 
residues are shown in bold type. 
quences of all other sequenced peptides of the RNA- 
linked protein, see fig.2. These two proteins are of 
identical size, and comparison of HPLC profiles of 
their tryptic peptides reveals marked similarity [lo]. 
Thus, we conclude that the cytoplasmic protein from 
mouse cells covalently bound to an RNA is pro- 
thymosin LY. 
3.2. Prothymosin cy is an evolutionary conserved 
protein 
The RNA preparation from human RD cells, bovine 
thymus and yeast S. cerevisiae cells was purified from 
the non-covalently bound proteins and radiolabelled 
with the ‘*? Bolton and Hunter reagent known to label 
proteins, but not RNA. The RNA fractionation by 
PAGE demonstrated that the ‘*‘I-labelled material 
identical to the mouse prothymosin wRNA complex 
was present in other cells, fig.3. Sensitivity of the 
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Fig.4. ‘25I tryptic peptide maps of the RNA-linked proteins from 
human (A), mouse (B) and yeast (C) cells. 
detected band to treatment with proteinase K and 
RNase T2 (fig.3, lanes 5 and 6) indicated the existence 
of both RNA and protein moieties in the material under 
study. Identification of the yeast RNA-protein complex 
is particularly interesting. It should be mentioned, 
however, that its amount in the yeast cells is approx. 
1000 times smaller than that in mammalian cells. 
‘251-labelled RNA-linked proteins from human, 
mouse (prothymosin a) and yeast cells were digested 
with trypsin, and two-dimensional fractionation of the 
resultant ‘*‘I-peptides was performed on thin-layer 
cellulose plates. Fig.4 demonstrates that the maps of 
RNA-linked proteins are nearly identical not only in 
human and mouse cells, but also in yeast. This suggests 
that the RNA-linked protein in diverse cells is identical 
or very similar to prothymosin (Y, and that the structure 
of this protein is highly conserved from yeast to man. 
Fig.3. ‘251-labelled covalent RNA-protein complexes from human 
(l), mouse (2), bovine (3) and yeast (4) cells are very similar. Lanes 
5 and 6, yeast RNA-protein complex treated with RNase T2 and 
proteinase K, respectively. An autoradiograph of 8% PAG is shown. 
Lane 7, HPLC-purified mouse RNA-protein complex stained with 
methylene blue. 
4. DISCUSSION 
Recently we have identified, in the cytoplasm of 
mouse cells, a 13 kDa protein covalently bound to the 
5 ‘-end of a small RNA molecule [2]. The amino acid 
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sequence of several tryptic peptides presented in this 
paper demonstrates that this protein is prothymosin U. 
Presence of the covalently linked RNA was not 
discovered for prothymosin u earlier. Prothymosin CY, 
an exceptionally acidic protein, was claimed to possess 
immunomodulating activity [3], and was classified as a 
thymic hormone. However, prothymosin CY lacks some 
features, which are characteristic of peptide hormones: 
it is expressed in a wide variety of tissues [4] and lacks 
a N-terminal signal sequence [4,5]. The data on its 
subcellular distribution are contradictory, indicating 
either nuclear [6,7], or cytoplasmic localization [ll]. 
Our study definitely indicates that prothymosin cy, 
when bound to an RNA, is located preferentially in the 
cytoplasm [2]. It cannot be excluded, however, that the 
protein-bound RNA can affect the subcellular localiza- 
tion of prothymosin cy. 
The primary structure of prothymosin a from a 
number of mammalian cells has been established, and 
minor amino acid substitutions were observed 
[4,5,8-lo]. Our finding that prothymosin a from 
higher eukaryotes is well-conserved is consistent with 
these data. However, as far as we know, this is the first 
report demonstrating the presence of prothymosin (Y in 
an organism other than vertebrates. It seems obvious 
that the immunomodulating activity of prothymosin LY 
is not its sole function. High evolutionary conservation 
of prothymosin (Y, from yeast to man, could possibly 
testify to its fundamental role in the cell. 
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